Experimental and Clinical Pharmacology
Janus kinase inhibitors in rheumatoid arthritis: Clinical applications
- Jennifer Walker, Malcolm Smith
- Aust Prescr 2014;37:158-60
- 1 October 2014
- DOI: 10.18773/austprescr.2014.062
Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.
Despite the advent of biological therapies for rheumatoid arthritis, many patients continue to experience unacceptable levels of disease. Furthermore, biological drugs have to be administered parenterally.
Janus kinase inhibitors are oral drugs. They interfere with signalling through type I and II cytokine receptors which have been shown to be critical in rheumatoid arthritis.1
Tofacitinib is an oral Janus kinase inhibitor with preferential inhibition of Janus kinase 3 and 1 over Janus kinase 2. It has an oral bioavailability of 74% and a mean elimination half-life of approximately three hours. Most (70%) of the drug is metabolised (CYP3A4 predominant) and 30% is renally excreted.2
Tofacitinib 5 mg twice a day has recently been approved by the US Food and Drug Administration for moderate to severe rheumatoid arthritis refractory to disease-modifying treatments.3
In phase II studies, tofacitinib was superior to placebo when added to methotrexate in patients with rheumatoid arthritis.4,5 Responses were observed quickly, often within one week. Furthermore, small numbers of patients were able to switch from adalimumab to tofacitinib without difficulty.6 In the initial studies, tofacitinib was tolerable at doses of 5 mg and 10 mg twice daily.
Several phase III trials have been conducted to assess the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (see Table). The American College of Rheumatology 20 criteria (ACR 20) were used to measure response rates (see Box).
A six month, double-blind study enrolled 611 patients who had not had an adequate response to at least one non-biological or biological disease-modifying drug. Patients received placebo or tofacitinib 5 mg or 10 mg twice daily in addition to usual care. Antimalarial drugs, non-steroidal anti-inflammatory drugs and glucocorticoids (≤ 10 mg prednisone/day) were permitted but all other disease-modifying drugs were discontinued for the trial.
A clinical benefit was demonstrated, but there was no significant increase in the number of patients entering remission according to disease activity score criteria.7 This suggested that while tofacitinib is effective as a monotherapy, additional disease-modifying therapy may be required.
Another study assessed tofacitinib as an add-on therapy in patients who had not responded adequately to methotrexate. This was a 12-month study of 717 patients on stable doses of methotrexate. They were given tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg every two weeks, or placebo. The study showed similar clinical benefit with the active treatments over placebo as well as an increase in numbers of patients entering remission at six months (based on a disease activity score).8
Responses among patients with more resistant disease have also been assessed. A six-month study enrolled 399 people who had not responded to at least one tumour necrosis factor inhibitor. Patients were randomised to placebo or tofacitinib (5 mg or 10 mg twice a day). After three months, patients who received placebo were transferred to tofacitinib. Once again, significant improvements were observed in ACR 20 response rates after three months and on a disability questionnaire (Health Assessment Questionnaire-Disability Index). However, among these patients with more resistant disease, there was no significant increase in rates of remission.9
The ORAL Sync study, reported as a conference abstract, assessed the addition of tofacitinib to treatment in patients who had ongoing disease despite receiving disease-modifying drugs. This trial design is likely to most closely reflect current clinical practice. Again, the study showed an improved response rate and disability score with tofacitinib, and a significant increase in the number of patients achieving remission.10
More recently, 12-month data looking at radiological outcomes with tofacitinib and methotrexate suggest that tofacitinib inhibits structural progression, both as solo therapy (to a greater level than methotrexate) and with background methotrexate use.11,12
The most common adverse events with tofacitinib were diarrhoea, nasopharyngitis, urinary tract infection, nausea and headache. The risk of infection is an important consideration, although a recent meta-analysis concluded that it was similar to the risk with biological therapies.
There have been 12 cases of tuberculosis reported in the trial cohorts, 11 of whom initially screened negative for the disease. Ten cases occurred in countries endemic for tuberculosis.
The incidence of herpes zoster is also increased with tofacitinib. In a pooled analysis of phase II, III and long-term extension studies (4789 patients with 5651 patient-years of tofacitinib treatment), 239 patients experienced herpes zoster. One case was multidermatomal, none involved visceral dissemination and there were no fatalities.13
Pooled analyses favour a 5 mg twice-daily dose of tofacitinib to reduce the risk of serious infection (seen in long-term extension studies). The transient effects of tofacitinib mean that its immunomodulatory effect can be rapidly reversed if sepsis occurs.9,14,15
Hyperlipidaemia has been consistently observed in the trials and may relate to inhibition of interleukin-6 signalling.14 Atorvastatin appears to reduce the increase in cholesterol,16 but long-term cardiovascular effects will need to be assessed in the future.
Elevations in liver aminotransferases, neutropenia, thrombocytopenia and anaemia have all been reported. Changes are generally mild. A small rise in serum creatinine has been noted, but at this stage has not been clinically significant.14,15 As yet, there has been no reported increase in malignancy, but long-term data are still needed.
Tofacitinib has shown promising results in phase II trials in other autoimmune diseases including ulcerative colitis and psoriasis. It is also being assessed as an immunosuppressant in renal transplant recipients.17-19
Tofacitinib is not yet available in Australia, but its release will provide an alternative option and effective oral treatment for patients with rheumatoid arthritis resistant to standard therapy. While initial data are promising, longer-term studies are required to better assess the risk of malignancy, opportunistic infection and radiological changes. Other Janus kinase inhibitors are currently undergoing clinical trials for rheumatoid arthritis.3
Conflict of interest: none declared.
Professor, Department of Rheumatology, Repatriation General Hospital, Adelaide